REGENERON PHARMACEUTICALS (RGO.DE) Stock Income Statement
Europe - Frankfurt Stock Exchange - FRA:RGO - US75886F1075 - Common Stock
673.6 EUR
+0.6 (+0.09%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 14.25B | 14.20B | 13.12B | 12.17B | 16.07B | |||
| Cost Of Goods | 1.96B | 1.84B | 1.71B | 1.30B | 2.21B | |||
| Gross Profit | 12.29B | 12.36B | 11.40B | 10.87B | 13.87B | |||
| Operating Expenses | 8.36B | 8.14B | 7.07B | 5.62B | 4.64B | |||
| Research and Development | 5.16B | 5.13B | 4.44B | 3.59B | 2.86B | |||
| Selling, General, and Administrative Expenses | 3.20B | 2.95B | 2.63B | 2.12B | 1.82B | |||
| Operating Income | 3.93B | 4.22B | 4.34B | 5.25B | 9.22B | |||
| Interest Income/Expense | 1.42B | 773.40M | 172.20M | -99.20M | 328.80M | |||
| Other Income/Expense | 38.90M | 15.80M | -20.00M | 219.10M | 50.20M | |||
| Non Recurring Items | -245.50M | -227.30M | -288.40M | -513.80M | -275.70M | |||
| Income Before Taxes | 5.15B | 4.78B | 4.20B | 4.86B | 9.33B | |||
| Income Tax | 567.10M | 367.30M | 245.70M | 520.40M | 1.25B | |||
| Net Income | 4.58B | 4.41B | 3.95B | 4.34B | 8.08B | |||
| EBITDA | 4.46B | 4.70B | 4.76B | 5.59B | 9.51B | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | 41.78 | 38.34 | 34.77 | 38.22 | 71.97 | |||
| Non GAAP EPS | 45.01 | 45.64 | 43.78 | 42.40 | 71.38 | |||
| Statistics | ||||||||
| Gross Profit Margin | 86.28% | 87.01% | 86.94% | 89.31% | 86.28% | |||
| Profit Margin | 32.13% | 31.07% | 30.14% | 35.64% | 50.25% | |||
| Operating Profit Margin | 27.61% | 29.70% | 33.05% | 43.15% | 57.38% | |||
All data in USD